Justin Hirsch
@Octagon Capital Advisors Lp
Latest period2024 - Q3ReportedManaged Assets$642.902MTotal holdings41
Assets growth rate1.05%Assets growth rate (2-Q avg)-11.35%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Octagon Capital Advisors Lp's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 41 positions.
Assets under management
The assets under management (AUM) of Octagon Capital Advisors Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 642.902M in assets, with a quarterly growth rate of 1.05% and a 2-quarter average growth rate of -11.35%. The portfolio is managed by Justin Hirsch, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
VRDNViridian Therapeutics Inc
| 3.08% | $19.793M 870,000 shares@ $22.75 avg price | Increased 40.33% |
CATXPerspective Therapeutics Inc
| 2.96% | $18.987M 1.422M shares@ $13.35 avg price | Decreased -10% |
MNMDMind Medicine Mindmed Inc
| 2.68% | $17.172M 3.018M shares@ $5.69 avg price | Increased 40.18% |
COGTCogent Biosciences Inc
| 2.2% | $14.094M 1.305M shares@ $10.8 avg price | New Position |
BBIOBridgebio Pharma Inc
| 2.19% | $14.054M 552,000 shares@ $25.46 avg price | Decreased -20% |
PHVSPharvaris N V
| 1.79% | $11.491M 620,470 shares@ $18.52 avg price | New Position |
DYNDyne Therapeutics Inc
| 1.47% | $9.437M 262,726 shares@ $35.93 avg price | Decreased -77.75% |
TSHATaysha Gene Therapies Inc
| 1.43% | $9.19M 4.572M shares@ $2.01 avg price | |
GOSSGossamer Bio Inc
| 1.41% | $9.063M 9.188M shares@ $0.99 avg price | |
ALVRAllovir Inc
| 1.41% | $9.057M 11.202M shares@ $0.81 avg price | Increased 14.31% |